Arbidol maximum caps. 200mg 10 pieces

$11.67

Arbidol maximum caps. 200mg 10 pieces

Quantity:

Description

Composition
Active substance:
1 capsule contains: umifenovir hydrochloride monohydrate (calculated as hydrochloride umifenovir) – 200 mg.
Excipients:
Potato starch – 52.67 mg, Microcrystalline Cellulose – 11.20 mg Colloidal silicon dioxide (Aerosil) – 2.80 mg, povidone (Kollidon 25) – 7.73 mg Calcium stearate – 2.80 mg sodium croscarmellose – 2.80 mg, the mass of the contents of capsules – 280 mg.
Hard gelatin capsules №0:
The composition of the capsule shell (body and cap): titanium dioxide (E 171) – 1.92 mg, gelatin – 94.08 mg. The total weight of the capsule – 376 mg.
Description:
Hard gelatin capsules № 0 white. Capsule contents – mixture containing granules and powder of white or white to greenish yellow or cream tint color to light yellow or light yellow color with a greenish hue.
Product form:
Capsules 200 mg.
10 capsules in blisters of PVC film and aluminum foil printed patent. 1 or 2 outline package with instructions for use placed in a pile of cardboard.
Contraindications
Hypersensitivity to the drug, age under 12 years old.
Dosage
200 mg
Indications
Prevention and treatment in adults and children from 12 years: influenza A and B, and other acute respiratory viral infections (including complicated by bronchitis, pneumonia), severe acute respiratory syndrome (SARS);
Combined therapy of acute intestinal infection rotavirus etiology in children older than 12 years.
Combined therapy of chronic bronchitis, pneumonia, and recurrent herpetic infection.
Prevention of postoperative infectious complications.
Interaction with other drugs
In the appointment of other drugs adverse effects were noted.
Overdose
It is not checked.
pharmachologic effect
Pharmacological group:
An antiviral agent.
Pharmacodynamics:
An antiviral agent. Specifically inhibits the in vitro influenza viruses A and B (Influenzavirus A, B), including highly subtypes A (H1N1) pdm09 and A (H5N1), as well as other viruses – activators SARS (coronavirus (Soronavirus) associated with severe acute respiratory syndrome ( SARS), rhinovirus (rhinovirus), Adenova-rus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (paramyxovirus)). According to the mechanism of the antiviral action relates to inhibitors of fusion (fusion), interacts with hemagglutinin of the virus and prevent fusion of lipid shell of a virus and cellular membranes. Has a moderate immunomodulatory effect, increases resistance to viral infections. It possesses interferon-inducing activity – in the study in mice induction of interferon was observed after 16 h and remained high titers of interferon in the blood up to 48 hours after administration. It stimulates cellular and humoral immune responses: it increases the number of lymphocytes in the blood, in particular T-cells (CD3), increases the number of T-helper (CD4), without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer cells (NK-cells).
Therapeutic efficacy for viral infections manifest in reducing the duration and severity of the disease and its main symptoms as well as reducing the incidence of complications associated with viral infection, and bacterial exacerbations of chronic diseases.
It refers to preparations of low toxicity (LD50> 4 g / kg). It does not have any negative impact on the human body when administered orally in the recommended dosages.
Pharmacokinetics. Rapidly absorbed and distributed to organs and tissues. Maximum concentration in plasma when receiving a dose of 50 mg is achieved in 1.2 hours, in a dose of 100 mg – 1.5 hours is metabolized in the liver.. The half-life is 17-21 h. About 40% is excreted unchanged, primarily in the bile (38.9%) and the minor kidneys (0.12%). During the first day shows 90% of the administered dose.
Pregnancy and breast-feeding
In animal studies there was no evidence of harmful effects on pregnancy, embryo-fetal development, labor and postnatal development.
Use of the drug Arbidol® maximum in the first trimester of pregnancy is contraindicated.
In the second and third trimester of pregnancy Arbidol® maximum it can only be used for the treatment and prevention of influenza and in the event that the anticipated benefits to the mother outweighs the potential risk to the fetus. Benefit / risk ratio is determined by the attending physician.
It is not known whether Arbidol® gets maximum in the breast milk of lactating women. If necessary, use Arbidol® maximum should stop breastfeeding.
Conditions of supply of pharmacies
Without a prescription.
side effects
Rarely – allergic reactions.
special instructions
Shows no central neurotropic activity and can be used in medical practice in people of different professions, including require attention and coordination of movements (transport drivers, operators, etc.).
Storage conditions
Store at a temperature not higher than 25 C. Keep out of reach of children.
Dosing and Administration
Inside, before meals. Single dose for adults and children over 12 years – 200 mg (1 capsule).
For non-specific prevention and treatment of influenza and other acute respiratory viral infections:
Nonspecific prevention of influenza and other ARI: • for preventing nonspecific during epidemics of influenza and other SARS · 200 mg (1 capsule) 2 times per week for 3 weeks. • in direct contact with patients with influenza and other SARS · 200 mg (1 capsule) once a day for 10-14 days.
Treatment of influenza and other ARI: • in uncomplicated · 200 mg (1 capsule) 4 times a day (every 6 hours) for 5 days. • during the development of complications (bronchitis, pneumonia and others.): 200 · mg (1 capsule) 4 times a day (every 6 hours) for 5 days then 1 single dose once a week for 4 weeks.
Combined therapy of acute intestinal rotavirus infections in children over 12 years: 200 · mg (1 capsule) 4 times a day (every 6 hours) for 5 days.
For non-specific prevention and treatment of severe acute respiratory sindromoma (SARS):
For nonspecific prevention of SARS (in contact with the patient): 200 · mg (1 capsule) once a day for 12-14 days.
For the treatment of SARS: 200 · mg (1 capsule) 2 times a day for 8-10 days.
In the treatment of chronic bronchitis, pneumonia, and herpes virus infection: · 200 mg (1 capsule) 4 times a day (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks.
Prevention of postoperative complications: · 200 mg (1 capsule) 2 days prior to surgery, then at 2 and 5 days after surgery.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Arbidol

There are no reviews yet.

Add your review